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 CURRENTOPINION The congenital myasthenic syndromes: expanding
genetic and phenotypic spectrums and refining
treatment strategies
An E. Vanhaesebroucka and David Beesonb
Purpose of review
Congenital myasthenic syndromes (CMS) are a group of heterogeneous inherited disorders caused by mutations
in genes encoding proteins whose function is essential for the integrity of neuromuscular transmission. This
review updates the reader on the expanding phenotypic spectrum and suggested improved treatment strategies.
Recent findings
As next-generation sequencing is taken into the clinic, its use is both continuing to unearth new causative genes
in which mutations underlie CMS and also broadening the phenotypic spectrum for known CMS genes. The
number of genes in which mutations may cause neuromuscular transmission defects has now passed 30. The
defective transmission may be part of an overall more complex phenotype in which there may be muscle,
central nervous system or other involvement. Notably, mutations in series of genes encoding proteins located in
the presynatic motor bouton have been identified. Rare cases of mutations in basal laminar proteins of the
synaptic cleft are coming to light and additional mutations/phenotypic features have been located in some of
the larger neuromuscular junction proteins such as AGRN and MUSK, where previously mutation screening by
sanger sequencing was time consuming and costly. Finally, there are more reports of the beneficial effects of
treatment with b2-adrenergic receptor agonists in patients, and the study of their action in disease models.
Summary
Recent studies of the CMS illustrate the increasing complexity of the genetics and pathophysiological
mechanisms involved. With therapy tailored for the underlying disease mechanism treatment, although
incomplete, is usually life-transforming. However, treatment for newly identified conditions in which
myasthenia is only one component within complex multisystem disorder will prove challenging.
Keywords
congenital myasthenic syndromes, ephedrine, next-generation sequencing, postsynaptic, presynaptic,
salbutamol, synaptic
INTRODUCTION
Congenitalmyasthenic syndromes (CMS) are a group
of rare inherited disorders of neuromuscular trans-
mission [1,2]. The syndromes share the clinical fea-
ture of fatigable muscle weakness, but the age of
onset, presenting symptoms, distribution of weak-
ness and response to treatment vary according to the
gene harbouring themutation(s) and the underlying
molecular mechanism that impairs signal transmis-
sion at the neuromuscular junction. Typical charac-
teristics of many myasthenic disorders are ptosis,
ophthalmoparesis, facial and bulbar weakness, and
generalized muscle weakness presenting in the neo-
natal period or early childhood. However, symptoms
can present in later childhood, adolescence or even
adulthood and the pattern of muscle weakness vary.
In a number of subtypes, there is marked limb-girdle
weakness but the eyes and facial muscles are spared,
and this can make differential diagnosis more chal-
lenging. Due to the more widespread adoption of
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next-generation sequencing the number of different
genes implicated in CMS continues to grow and is
now greater than 30 (Table 1). It is likely that muta-
tions in some of these newly recognized genes will be
exceptionally rare causes of CMS and will essentially
remain isolated case studies, whereas others will war-
rant inclusion in standard genetic screening panels.
Manyof themore recently identifiedmutations caus-
ing CMS are in proteins whose expression is not
restricted to the neuromuscular junction and, not
surprisingly,mutations in these genesmayoften give
rise to disorders with complex phenotypeswith vary-
ing levels of involvement of impairedneuromuscular
transmission.
In this review, we report on the expanding
number of ‘causative-genes’ in which mutations
that underlie impaired neuromuscular transmission
have been identified, we update on the growing
phenotypic spectrum for both new and better estab-
lished CMS subtypes, and review recent thinking on
treatment strategies.
PRESYNAPTIC CONGENITAL
MYASTHENIC SYNDROMES
It has become apparent that the presynaptic forms of
CMS can be subdivided into two main categories;
first, those involved in the synthesis and recycling
of acetylcholine (ACh) and second, those involved in
vesicle docking and transmitter release from the
nerve terminal. Genes harbouring CMS-causing
mutations in the ACh-recycling pathway include
SLC5A7, CHAT and SLC18A3, which encode the
high-affinity choline uptake transporter, cholineace-
tyltransferase and the vesicular ACh transporter,
respectively [3–5]. Mutations in CHAT have long
been established as a cause of a CMS characterized
by episodic apneas and respiratory crises early in life
that are often induced by infections or stress [4].
Between crises symptoms may be relatively mild
and the number of life-threatening crises reduces
with age so that by adolescence and adulthood
occurrence is very rare. SLC5A7 and SLC18A3
CMS subtypes in general are more severe than cho-
line acetyltransferase (CHAT)-CMS, and can lead to
fatal foetal akinesia during pregnancy, and they
share the same life-threatening apnoeic crises in
early life. In addition, patients are reported to have
marked ptosis, ophthalmoplegia, muscle fatigabil-
ity, and in some cases [3,5] of both SLC5A7 and
SLC18A3 CMS learning difficulties have been
noted, which, in the absence of hypoxic damage,
rarely if ever occurs in CHAT CMS. The reported
phenotype for SLC5A7CMSvarieswithmany show-
ing arthrogryposis/joint contractures at birth and
limited survival, but other are relatively mild.
Patients with mutations in the ACh recycling path-
way respond to cholinesterasemedication although
in the severe cases the effect is minimal. It is of note
that distal hereditary motor neuropathy type VII is
caused by dominantmutations in SLC5A7 [6,7], but
surprisingly there appears to be little phenotypic
overlap between the two disorders.
A second group of presynaptic syndromes fea-
tures proteins involved in neurotransmitter release
from the presynaptic nerve terminal. The soluble N-
ethylmaleimide-sensitive factor attachment protein
(SNARE) complex governs vesicle membrane dock-
ing, fusion and transmitter release from the presyn-
aptic terminal. Synaptobrevin (VAMP1), syntaxin
and synaptosomal-associated protein 25B (SNAP25B)
form the core of the SNARE complex. Synaptotagmin
2 (SYT2) acts as a sensor detecting the influx of
calcium following activation of voltage-gated cal-
cium channels and interacts with the SNARE com-
plex to trigger transmitter release. MUNC13
(UNC13A) is involved in assembly of the SNARE
complex. Mutations in VAMP1 [8,9], SNAP25B [10],
UNC13A [11] and SYT2 [12,13] have been found
underlie syndromes in which synaptic transmission
at the neuromuscular junction is impaired. However,
SNARE-mediated membrane fusion is an essential
feature of eukaryotic organisms and occurs at multi-
ple sites and thus impaired neuromuscular transmis-
sion isoftenonly likely tobeonecomponentwithina
wider multisystem disorder. For example, a de-novo
SNAP25B mutation gave rise to a case of reduced
quantal release from the motor nerve terminal, but
KEY POINTS
 Next-generation sequencing continues to expand the
number of genes/proteins harbouring mutations that
cause CMS.
 Many of the recently identified ‘CMS genes’ encode
presynaptic proteins involved in acetylcholine recycling
or neurotransmitter release.
 Many of the newly identified genes encode proteins
with functional roles that are not restricted to the
neuromuscular junction and thus myasthenia is often
only one component of a more severe and complex
clinical spectrum.
 b2-adrenergic receptor agonists are increasingly
helpful in tailoring treatment for different
CMS subtypes.
 However, symptomatic treatment of the neuromuscular
synapse will be of limited benefit for the more complex
multisystem disorders and these cases will require new
therapeutic strategies.
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also severe developmental delay, and ataxic gait and
dysarthria. By contrast with the majority of CMS,
SYT2mutations give rise to a dominant disorderwith
features of amotor neuropathy and a neuromuscular
transmission disorder resembling the autoimmune
Lambert–Eaton myasthenic syndrome in which
autoantibodies are directed against the presynaptic
voltage-gated calcium channels. Like the Lambert–
Eaton myasthenic syndrome, the syndromes arising
from mutations in vesicle docking and neurotrans-
mitter release mechanisms most commonly show
increment of compound muscle action potential
amplitudewithhigh-frequency repetitivenerve stim-
ulation. A more detailed review of the molecular
mechanisms and electrophysiology of the presynap-
tic CMS is given in [14
&&
].
Table 1. Congenital myasthenic syndromes
Site of defect Mechanism Gene Protein
Presynaptic Defects in ACh recycling SLC5A7 ChT
Defects in ACh synthesis CHAT ChAT
Defects in loading of ACh in synaptic
vesicles
SLC18A3 VAChT
Defects in synaptic vesicle docking,
priming, fusing and exocytosis
SNAP25B Soluble N-ethylmaleimide-sensitive factor attachment
protein receptor 25
UNC13A Munc 13
SYB1/VAMP1 Synaptobrevin-1/Vesicle associated membrane protein 1
SYT2 Synaptotagmin-2
PREPL Propyl-endopeptidase-like
Defects in axonal transport of proteins MYO9A Myosin IXA
Synaptic Acetylcholinesterase deficiency COLQ Collagen-tail subunit of acetylcholinesterase
Synaptic basement membrane defects COL13A1 Collagen type 13 a1
LAMA5 Laminin a5
LAMB2 Laminin b2
Defects in AChR clustering pathway AGRN Agrin
Postsynaptic Reduced numbers of AChR (AChR
deficiency)
CHRNE
(CHRNA1
CHRNB1
CHRND)
AChR subunits
Kinetic changes in AChR function (slow
channel syndromes)
CHRNA1
CHRNB1
CHRND
CHRNE
AChR subunits
Kinetic changes in AChR function (fast
channel syndromes)
CHRNA1
CHRND
CHRNB1
CHRNE
AChR subunits
Defects in AChR clustering pathway LRP4 LDL-related protein 4
MUSK Muscle-specific tyrosine kinase
DOK7 Downstream of kinase 7
RAPSN Rapsyn
Defect in skeletal muscle voltage-gated
sodium channel
SCN4A Sodium voltage-gated channel a4
Plectin deficiency PLEC Plectin
Preþpost Defective glycosylation ALG2 a-1,3-Mannosyltransferase
ALG14 UDP-N-acetylglucosaminyltransferase
DPAGT1 Dolichyl-phosphate N-acetyl-
glucosaminephosphotransferase 1
GFPT1 Glutamine-fructose-6-phosphate transaminase 1
GMPPB GDP-mannose pyrophosphorylase
ACh, acetylcholine; AChR, acetylcholine receptor; ChAT, choline acetyltransferase; ChT, choline transporter; COL13A1, collagen type XIII alpha 1; LRP4, LDL
receptor-related protein 4; VAChT, vesicular acetylcholine transporter.
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BASAL LAMINA-ASSOCIATED
SYNDROMES
Mutations in the collagen-like tail subunit (COLQ)
that anchors the asymmetric form of acetylcholines-
terase (AChE) to the basal lamina in the synaptic cleft
of the neuromuscular junction are an established
major cause of CMS. Some laminins subtypes are
selectively expressed at the neuromuscular synapse
and mouse models indicate a role in both synaptic
structure and signalling but CMS resulting from
mutations in laminin subunits are exceedingly rare.
Single case reports have identified a homozygous
mutation in laminin a5 (LAMA5) [15] and laminin
b2 (LAMB2) [16]. In each case, the neuromuscular
junction defect was reported in association with
additional nonmyasthenic phenotypic features, for
LAMA5 it was myopia and facial tics, for LAMB2 it is
Pierson syndrome [17] characterized by chronic renal
failure and neurodevelopmental problems. Collagen
type XIII alpha 1 (COL13A1) is a single-pass type II
transmembrane protein with a triple-helical collage-
nous ectodomain. It has main basic forms, one
anchored in the plasma membrane via the trans-
membrane domain, and the second results from
proteolytic cleavage of the ectodomain to produce
a soluble product that interacts with components of
the basal lamina.Mousemodels have shown that loss
of COL13A1 affects early maturation of neuromus-
cular junction structures on both pre and postsynap-
tic sides, and endplates remained small immature
and fragmented [18]. In keeping with these studies
of COL13A1 function a report on 16 cases from 11
independent kinships found clinical presentation
mostly at birth with hypotonia, and breathing and
feeding difficulties [19
&&
]. Respiratory crises related to
recurrent apnoea usually triggered by infectionswere
common. Bilateral nonfatigable ptosis in adulthood
andmarkedweakness of neck flexionwere character-
istic features. Patients respond to treatment with
salbutamol and 3,4-diaminopyridine in their early
years, but, whether treated or not, disease severity
improves over time so that in some cases by adult-
hoodmuscle strengthmay be normal [19
&&
,20]. Stud-
ies of COL13A1 mutations emphasis the role of
extracellular matrix proteins that are not part of
the AGRN–LDL receptor-related protein 4 (LRP4)–
MUSK–DOK7 signalling pathway in maturation of
the mature synapse.
AGRN is a large extracellular matrix proteogly-
can. It has several isoforms, and it is its neural
isoform that plays a key role inmaintaining synaptic
structure through binding the LRP4 which in turn
binds and activates MUSK [21]. Each of these three
proteins is relatively large, withmany exons, various
splicing isoforms and multiple functional domains.
The size and the number of exonswithin these genes
made them challenging to screen using standard
PCR and Sanger sequencing techniques. Next-gen-
eration sequencing has greatly facilitated mutation
detection within these genes and led to the a broad-
ening of the phenotypic spectrum for CMS due to
either AGRN [22,23] or MUSK mutations including
variants in MUSK giving rise to a late onset limb
girdle CMS [24
&
] isolated vocal cord paralysis [25] or
pregnancy-associated respiratory failure [26]. It is
likely that there will be increasing pick up of variants
within these genes but defining pathogenicity will
often require time-consuming and quite complex
functional studies.
GLYCOSYLATION PATHWAY
CONGENITAL MYASTHENIC SYNDROMES
The asparagine-linked (N-linked) glycosylation path-
way is a ubiquitous process present in all eukaryotic
cells where there is sequential attachment of sugar
moieties to amembrane lipid (dolichol) that are then
transferred to a protein. The addition and processing
of these glycans are crucial for the folding, assembly,
stabilityand intracellular transportofproteins.Muta-
tions in the genes which encode components of this
pathway are often devastating causing severe multi-
system disorders that may be fatal. However, a group
of CMS, characterized by a limb girdle pattern on
muscle weakness with little ocular or facial involve-
ment, are found to have mutations in proteins that
contribute to the early steps of this pathway [27–30].
Mutations within the same in genes, for example
DPAGT1, can lead to either a severe multisystem
disorder or a myasthenic disorder in which fatigable
muscleweakness is the only presenting symptom.An
article by Dong et al. [31
&&
] had shed light on what
may underlie these very different manifestations.
DPAGT1 encodes dolichyl-phosphate (UDP-N-ace-
tylglucosamine) N-acetylglucosaminephosphotrans-
ferase1and is theenzymeresponsible for the first step
in the assembly of the core glycan (Glc3Man9Glc-
NAc2) on the lipid dolichol. Crystallization of
DPAGT1 in its apo state,whenbound toUDP-GlcNac
or tunicamycin and functional studies of DPAGT1
enzymatic activity showed that mutations the cause
the multisystem disorder (CDG1j) are either null
(frameshift or nonsense mutations) or affects cata-
lytic activity, whereas those causing CMS tend to be
located further from the catalytic site and may
reduce protein expression/dimerization or modestly
decrease catalytic activity. The neuromuscular junc-
tion is known to be very heavily glycosylated and it
seems likely that it is sensitive to perturbations in
function caused by modest impairment of the early
steps of the N-linked glycosylation pathway. Uncov-
ering themolecular structure ofDPAGT1 shouldhelp
Peripheral nerve and neuromuscular junction disease
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predict the pathogenicity and severity of genetic
variants detected in the DPAGT1 [31
&&
].
UPDATE ON TREATMENT STRATEGIES
The current repertoire of drugs for use in CMS
includes as follows:
Drugs that increaseAChrelease, suchaspotassium
blockers (3,4-diaminopyridine); drugs that maintain
high ACh concentrations within the synaptic cleft,
such as AChE inhibitors (mainly pyridostigmine); b2-
adrenergic receptor agonists (ephedrine, salbutamol);
and ACh receptor (AChR) open-channel blockers (flu-
oxetine, quinidine) [1,32]. A diagrammatic represen-
tation of the neuromuscular junction and the site of
action for thesedrugsare showninFig. 1.The response
to treatment depends upon the subtype of CMS and
the underlying pathogenic molecular mechanism. A
number of recent reports have reviewed literature on
treatment andprovidedpotential algorithms for treat-
ments strategies [32–34].
For many years reversible, competitive AChE
inhibitors, such as pyridostigmine [35], were the
mainstay of treatment for myasthenia. By blocking
the action of AChE, the presence of ACh within the
synapse is prolonged thus giving a greater probabil-
ity of reaching the depolarization threshold for
generation of themuscle action potential. Although
effective for many CMS in others there was no clear
response and in some it was positively harmful.
Now, with greater understanding of the mutations
and molecular mechanisms underlying CMS treat-
ments can be tailored for the specific syndrome and
depending on diseases severity and patient response
this can include utilizing different combinations of
the drugs. Pyridostigmine is quite clearly contra-
indicated for endplate AChE deficiency due tomuta-
tions in COLQ [36] as there is already a deficit of
AChE function, and similarly in the dominant slow
channel syndrome increasing the level and duration
of ACh within the synaptic cleft is only likely to
exacerbate the disorder. The use of AChR open
FIGURE 1. Diagrammatic representation for the sites of action for commonly used drugs for congenital myasthenic syndromes
AChE, acetylcholinesterase inhibitors (neostigmine, pyridostigmine); 3,4-DAP, 3,4-diaminopyridine; open channel blockers
(quinidine, fluoxetine); b2-ADR agonists, b2-adrenergic receptor agonists (salbutamol, ephedrine). VGCC, voltage-gated
calcium channel; VGNC, voltage-gated sodium channel.
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channel blockers, fluoxetine or quinidine, can be
remarkably effective for some slow channel muta-
tions but the response is less marked for others.
Adrenergic agonists, in particular ephedrine, have
been used for the treatment ofmyasthenia, since the
1930s [37,38], but were largely replaced once AChE
inhibitors were found to be effective in symptomat-
ically treating myasthenia gravis [39]. Over the last
10–15 years, b2-agonists have re-entered as a main-
stream option in treatment. Clearly an alternative to
cholinesterase inhibitors was required for endplate
AChE deficiencies, and in these patients a beneficial
response to ephedrinewas reported [40]. However, it
was following the identification of DOK7mutations
as a major cause of CMS and their slow but remark-
able improvement with b2-agonist medication that
provided the impetus for its more widespread adop-
tion. It is now apparent that not only DOK7-CMS
but all the forms of CMS resulting frommutations in
the AGRN–LRP4–MUSK–DOK7 signalling pathway
for clustering AChR respond well to b2-agonists
although the response for AGRN-CMS tends to be
less pronounced. AChR deficiency patients on long-
term anticholinesterase medication have also been
found to benefit from b2-agonists. Long-term anti-
cholinesterase has been shown to affect neuromus-
cular transmission and motor endplate fine
structure [41], and so over time this treatment
may become less effective. It appears that b2 ago-
nists can alleviate these detrimental effects. Studies
of ‘knock out’ mouse models of the neuromuscular
junction identified that neurotransmission itself act
to disperse AChR and disrupt synaptic structures
and that this is countered by the input from the
AGRN–LRP4–MUSK–DOK7 signalling pathway
[42,43] (Fig. 2). A plausible way that b2 agonists
FIGURE 2. Pathways of synaptic disassembly and assembly at the neuromuscular junctions. Acetylcholine, released from the
nerve terminal following a nerve stimulus, activates acetylcholine receptors. In addition to instructing muscle contraction,
acetylcholine receptor activation is thought to disperse the tightly packed acetylcholine receptor away from the nerve terminal,
which initiates synaptic disassembly. The agrin-induced acetylcholine receptor clustering pathway promotes synaptic assembly
and thus counteracts the negative effect of acetylcholine on synaptic structure. Agrin is released from the nerve terminal, then
binds LDL receptor-related protein 4, which activates MUSK and DOK7 and ultimately results in aggregation of postsynaptic
acetylcholine receptors and maturation of the synaptic apparatus.
Peripheral nerve and neuromuscular junction disease
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have their beneficial effect is through enhancing
the signal downstream that comes from the
AGRN pathway and thus enhances and stabilize
neuromuscular junction structure.
Little is known at themolecular level about how
b2 agonists are exerting their effect at the neuro-
muscular junction, but a number of reports have
begun to address this. Recentlyb2-adrenergic recep-
tors were found to be present in higher densities at
the postsynaptic membrane [44,45
&
]. In addition, it
is now thought that neuromuscular junctions
might receive direct sympathetic innervation
[44,46]. b2-adrenergic agonists do not have an
immediate functional effects at the neuromuscular
junction at doses clinically attainable [47] but fresh
studies, using cell models, zebrafish or mouse mod-
els of myasthenia, all show that the b2-adrenergic
receptor has a role inmaintenance or enhancement
of the postsynaptic structure of the neuromuscular
junction [45
&
,48,49
&
].
CONCLUSION
Many cases of CMS can be given effective symptom-
atic treatment with the drugs that are currently
available once an understanding of the disease
mechanism resulting from the mutation(s) is
known. This often requires a balance between med-
ication that directly enhances neuromuscular trans-
mission and medication that helps maintain
synaptic structure. However, clinical application
of next-generation sequencing is revealing muta-
tions in which myasthenia is only one component
in a much wider disease phenotype. Symptomatic
treatment of the neuromuscular junction is not
always effective in severe cases of CMS and may
not be appropriate for disorders in which myasthe-
nia is the minor component in a multisystem disor-
der.Wemay now be reaching the time when it is apt
to explore how novel gene therapies might be
applied to these rare genetic disorders.
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